Ensysce Biosciences effects 1-for-12 reverse stock split effective March 31, 2023

Ensysce Biosciences, Inc.

Reverse stock split at 1-for-12 ratio, effective 12:01 am on March 31, 2023.
New CUSIP number 293602405; no fractional shares issued, cash paid in lieu.
Exercise prices and shares of warrants, options, and RSUs adjusted proportionately.
Series A Preferred Stock redeemed in connection with the reverse split.
Stockholders approved the split on March 23, 2023; board set ratio at 1-for-12.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Ensysce Biosciences, Inc.: Amended certificate of incorporation to effect a 1-for-12 reverse stock split (effective 2023-03-31).

Change: charter amendment
Effective: 2023-03-31

Exact text from the filing

On March 28, 2023, Ensysce Biosciences, Inc. (the "Company" or "we" or "our") filed an amendment to the Company’s Third Amended and Restated Certificate of Incorporation (as amended to date, the "Certificate of Incorporation"), with the Secretary of State of the State of Delaware to effect a one-for-twelve (1-for-12) reverse stock split (the "Reverse Stock Split") of our common stock, par value $0.0001 (the "Common Stock").

View on SEC.gov

42 governance changes filed in the last 30 days. Browse all governance changes →

Ensysce Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-009637

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.